Skip to content

DEBA PHARMA

Active Public limited companyfounded 1988active for 38 yearsDumolinlaan 13, 8510 KortrijkKBO/BCE: BE 0434.737.865 subsidiary of

Lifetime

20 annual accounts with figures on one time axis, 37 filings since 1989
peak of €2.9m in 2025
€2.9m▲ 15.9%
peak of €2.1m in 2025
€2.1m▲ 15.8%
peak of €6.2m in 2025
€6.2m▲ 4.0%
€339,319▼ 7.8%
peak of 1.2 FTE in 2025
1.2 FTE▲ 71.4%
Board5 names since 2013
5 directors and 4 others
Owners
98.67%
Documentsfilings and deeds
24-07-20267 days before the deadline
2025abbreviated format
Gross margin from €2.5m to €2.9mStaff from 0.7 FTE to 1.2 FTE5 directors reappointed 06-10Dividend €1.8mCash from €2.3m to €1.3m

Key points

from the 2025 annual accounts

Equity

€6.2m ▲ 4.0%
6.02024+2.1Profit-1.8Dividend-0.06Other6.22025

DEBA PHARMA paid out €1.8m in dividends. That is 86% of the 2025 profit.

Filings

37 annual accounts since 1989
AprilJune31 JulyOctober1990200020102020

The last five annual accounts were filed 4 to 17 days before the end of the period.

Position in the sector

94.4%

Higher solvency than 95% of companies in pharmaceuticals. The sector median is 38.7%, over 84 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 31,390 companies had the same profile as DEBA PHARMA has now. Each dot stands for 79 companies, two years later.

93.4%
were still trading
6.0%
stopped another way
0.5%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more

Another 0.1% stopped without a precise date, possibly only after those two years.

Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 31,390 companies, not a prediction for DEBA PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Managing director
Director
Director, , since 30-06-2025
Director
Director
  • 98.67%equity €6.3m (2025) · annual accounts 30-09-2025 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0434737865
5 directors reappointed (managing director), , , and · acts as permanent representative · General meeting of 30-06-2025 · Gazette deed
Purpose change · Amendment of the articles “De aankoop, productie en verkoop in voedingssupplementen, medische en paramedische producten, materialen en…” (deed in Dutch) · Gazette deed
3 directors appointed , and · General meeting of 30-09-2020 · Gazette deed
All 53 events

Comparable companies

same main activity, similar in size and age
Company
DEBA PHARMA Kortrijk €6.6m €2.9m 94.4% 1.2
CRESSANA Zwalm €3.3m €1.5m 84.1% 4.4
TRUVION HEALTHCARE Temse €3.2m €1.6m 41.4% 10.1
Jeandarme Sint-Truiden €1.6m €0.8m 11.7% 7
ASTEL MEDICA Neupré €2.6m €2.1m 53.2% 14.6
BETAPLUS PHARMA Woluwe-Saint-Lambert €24.9m €2.7m 89.8% 11.3
BIVIT Wevelgem €4.4m €3.1m 17.8% 23.5

These companies have the same main activity as DEBA PHARMA: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201). They are comparable in size and age: total assets between €1.6m and €25m, founded between 1974 and 2005.

Official details

Source: KBO
Status
Active since 15-07-1988Normal situation
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201and 2 others
Joint committee
119Food trade · annual accounts 2024
Establishment unit
2.039.328.0978510 Kortrijk, registered on 27-07-1988
Financial year end
31 December
Peppol
Reachable since 23-12-2025
Company details

Annual accounts 2025

≈ €5.0mestimated
€6.6m▲ 3.2%
Employeeson 31-12-2025
2=
Filing
Filed on 24-07-2026, 7 days before the end of the filing period
Financials

Insights on DEBA PHARMA

DEBA PHARMA files the abbreviated format. That format states no turnover. The gross margin rose from €718,341 in 2006 to €2.9m in 2025.

holds 98.67% of the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about DEBA PHARMA

What is the company number of DEBA PHARMA?
The company number of DEBA PHARMA is 0434.737.865. The VAT number is the same number with BE in front: BE 0434.737.865.
Where is DEBA PHARMA based?
The registered office is at Dumolinlaan 13, 8510 Kortrijk.Company details
What does DEBA PHARMA do?
According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21201).
What is the legal form of DEBA PHARMA?
DEBA PHARMA is a public limited company (NV).
When was DEBA PHARMA founded?
DEBA PHARMA was founded on 15-07-1988.
Is DEBA PHARMA still active?
Yes, DEBA PHARMA is an active enterprise in the KBO register.
How many employees does DEBA PHARMA have?
DEBA PHARMA had an average of 1.2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does DEBA PHARMA fall under?
In its 2024 annual accounts, DEBA PHARMA states joint committee 119 (Food trade).
What is the turnover of DEBA PHARMA?
The turnover in financial year 2025 is about €5.0m. This figure is estimated from the gross margin of €2.9m and 1,577 comparable companies of the same size. It probably lies between €3.4m and €8.3m. It is a rough estimate.
Is DEBA PHARMA profitable?
In financial year 2025, DEBA PHARMA made a profit of €2.1m.
Where can I find the annual accounts of DEBA PHARMA?
DEBA PHARMA filed 37 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of DEBA PHARMA due?
DEBA PHARMA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.